myNEO

Ottergemsesteenweg Zuid 808 B511

9000 Gent

BE

myNEO

Foundation date

01/12/2018

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

MyNEO is a Ghent-based biotech company that identifies, validates and explores therapeutic applications of personalized cancer vaccines starting from the patients tumor-specific mutations. The ImmunoEngine bioinformatic platform reports the personalized neoantigens of a patient sample, and is integrated within our end-to-end solution including state-of-the-art sequencing methods, in-vitro immunogenicity tests, and personalized mRNA vaccine construct production.

Upcoming events

Latest news

  • Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING®

    Monday August 8th 2022

  • S-Biomedic welcomes Pascal Yvon to lead its B2B commercial activities

    Tuesday August 2nd 2022

  • Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial

    Monday August 1st 2022

Jobs by myNEO